Early Administration of Anti–SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients

• DOI: 10.1016/j.ekir.2022.03.020
• Publication Date: 2022-03-26T22:18:18Z
• Authors: Juliette Gueguen; Charlotte Colosio; Arnaud Del Bello; Anne Scemla; Yohan N’Guyen; Claire Rouzaud; Claudia Carvalho-...; Gabriela Gautier ...; Pierre Tremolières; A. Jalal Eddine; Christophe Masset; Olivier Thaunat; Melchior Chabannes; Paulo Malvezzi; Pierre Pommerolle; Lionel Couzi; Nassim Kamar; Sophie Caillard; Philippe Gatault
• Keywords: 2019-20 coronavirus outbreak; Immunosuppression

Kidney transplant recipients (KTRs) are prone to develop severe COVID-19 and less well protected by vaccine than immunocompetent subjects. Thus, the use of neutralizing anti-SARS-CoV-2 monoclonal antibody (MoAb) confer a passive immunity appears attractive in KTRs.We performed French nationwide study compare COVID-19-related hospitalization, 30-day admission intensive care unit (ICU), death between KTRs who received an early infusion MoAb (MoAb group) did not (control group). Controls were identified from COVID-SFT registry (NCT04360707) using propensity score matching with following covariates: age, sex, delay transplantation infection, induction maintenance immunosuppressive therapy, initial symptoms, comorbidities.A total 80 February 2021 June 2021. They matched 155 controls. ICU, frequently observed group (35.0% vs. 49.7%, P = 0.032; 2.5% 15.5%, 0.002; 1.25% 11.6%, 0.005, respectively). No patient required mechanical ventilation group. The number patients treat prevent 1 was 9.7.The mild form largely improved outcomes KTRs.